Post-COVID symptoms reported at asynchronous virtual review and stratified follow-up after COVID-19 pneumonia

Taylor, Rebecca R; Trivedi, Bhavi; Patel, Neena; Singh, Richa; Ricketts, William; Elliott, Katharine; Yarwood, Marcus; White, Vlc; Hylton, Hannah; Allen, R J; Thomas, Gavin; Kapil, Vikas; McGuckin, Rachel; Pfeffer, Paul

doi:10.7861/clinmed.2021-0037

Cited by 33 publications

(29 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We also found the symptom burden not to be related to characteristics of the previous hospital stay, particularly the severity of COVID-19, which goes along with data from shorter follow-up times in previous studies [36,61,[63][64][65]. In some studies, however, a positive correlation between the severity of the COVID-19 disease and the symptom burden at follow-up had been found [15,26,35,58,60,66].…”

Section: Discussionsupporting

confidence: 83%

Associations of Post-Acute COVID syndrome with physiological and clinical measures 10 months after hospitalization in patients of the first wave

Staudt

Jörres

Hinterberger

et al. 2022

European Journal of Internal Medicine

View full text Add to dashboard Cite

Background: For a better understanding of the factors underlying the Post-Acute COVID Syndrome, we studied the relationship between symptoms and functional alterations in COVID-19 patients 10 months after hospitalization. Methods: One-hundred-one patients hospitalized between March 1st and June 30th 2020 participated in a followup visit for an assessment of clinical history, comorbidities, lung function, physical capacity and symptoms, including the SGRQ for health-related quality of life, PHQ-9-D for depression, and SOMS-2 J for somatoform disorders. Data were analyzed by univariate comparisons and multiple logistic regression analyses. Results: Median age was 60 years, 42% were female, 76% had at least one comorbidity, the median length of the hospital stay was 8 days, 19% had been on the ICU. The most prevalent symptoms included shortness of breath (49%), fatigue (49%) and cognitive impairment (39%). Signs of major depression (PHQ-9-D ≥ 10) occurred in 28%/2% (p < 0.05) of patients with/without self-reported cognitive impairment, with median total SGRQ score being 25.4/5.3 (p < 0.05). There were associations between shortness of breath and BMI, SGRQ and hemoglobin levels; between fatigue, SGRQ and PHQ-9-D; and between cognitive impairment and PHQ-9-D (p < 0.05 each) but not with lung function or physical capacity. Characteristics of the acute disease were not related to symptoms. Conclusions:The findings demonstrate that 10 months after discharge from a hospital stay due to COVID-19, the percentages of patients with symptoms were high. Symptoms showed a consistent pattern but could not be attributed to altered lung function or physical capacity. Our results suggest a role for alternative etiologies including psychosocial factors.

show abstract

Section: Discussionsupporting

confidence: 83%

Associations of Post-Acute COVID syndrome with physiological and clinical measures 10 months after hospitalization in patients of the first wave

Staudt

Jörres

Hinterberger

et al. 2022

European Journal of Internal Medicine

View full text Add to dashboard Cite

show abstract

“…For example, Huang et al ( 3 ) also reported that fatigue or muscle weakness and sleep difficulties were the most common symptoms at the 6-month follow-up. In another study, Taylor et al found that at an average 18 weeks post-acute infection, the COVID-19 survivors had a median of two ongoing physical complaints, with fatigue the most common ( 44 ). All these data illustrate that the majority of COVID-19 survivors suffer from at least one ongoing symptom at 3–6 months follow-up, with fatigue and sleep difficulty the most frequently reported symptoms.…”

Section: Discussionmentioning

confidence: 99%

Post-traumatic Stress Disorder Symptoms and Quality of Life of COVID-19 Survivors at 6-Month Follow-Up: A Cross-Sectional Observational Study

Huang

Zhang

et al. 2022

Front. Psychiatry

View full text Add to dashboard Cite

Background: Post-traumatic stress disorder (PTSD) is the most common psychiatric sequelae among novel coronavirus disease (COVID-19) patients. The aim of this study was to determine the prevalence of PTSD symptoms, PTSD-related factors, and its relationship with quality of life at long-term follow-up in hospitalized COVID-19 survivors.Methods: A cross-sectional study was undertaken to evaluate the health consequences of hospitalized COVID-19 survivors. All participants were interviewed face-to-face through a series of questionnaires: a researcher-developed symptom questionnaire, the Post-traumatic Stress Disorder Checklist–Civilian Version, the Generalized Anxiety Disorder 7-item, and the 36-item Short Form.Results: A total of 574 participants were enrolled with an average age of 57 years. The median follow-up time post-discharge was 193.9 days (SD = 15.32). Among the participants, 77.9% of survivors presented with at least one symptom, where fatigue or muscle weakness (47.9%) was reported the most frequently, followed by chest distress (29.4%) and sleep difficulty (29.4%). The prevalence of PTSD was 11.15% [95% confidence interval (CI): 8.56, 13.73] with a cut-off score of 44. Factors such as respiratory symptoms [odds ratio (OR): 3.53; 95% CI: 1.68–7.42], anxiety (OR: 14.64; 95% CI: 7.09–30.21), and sleep difficulty (OR: 2.17; 95% CI: 1.14–4.16) were positively related to PTSD. Those COVID-19 survivors with potential PTSD had significantly lower quality of life than those without (P < 0.05).Conclusion: Our study illustrated that a significant number of COVID-19 survivors were suffering from physical or mental distress to varying degrees at 6 months post-discharge. People with PTSD were more likely to experience persistent respiratory symptoms and sleep difficulty, as well as anxiety and a decreased quality of life. Such survivors require greater attention to their mental health, particularly the PTSD symptoms at the early phase, which may play an important role in the recovery of both the physical and psychological health of COVID-19 survivors.

show abstract

“…Neurological symptoms included: (1) anosmia [ [11] , [12] , [13] , [14] , [15] , [16] , [17] , [18] , [19] , [20] ] (2) dysgeusia [ [11] , [12] , [13] , [15] , [16] , [17] , [18] ] (3) headache [ 11 , [13] , [14] , [15] , [16] , 18 , 21 , 22 ] (4) any cognitive dysfunction [ 13 , 14 , 16 , [18] , [19] , [20] , [21] ] (see: Supplemental Table 2) (5) any fatigue [ 11 , 13 , 14 , 16 , 18 , 19 , [21] , [22] , [23] , [24] , [25] ] (fatigue/malaise [ 11 , 13 , 14 , 16 , 18 , 19 , [21] , [22] , [23] ], chronic fatigue syndrome [ 24 ], post exertional malaise [ 21 ]) (6) pain (neuropathic pain [ 15 , 23 ], myalgia [ 11 , 12 , [14] , [15] , [16] , 18 , 21 , …”

Section: Methodsmentioning

confidence: 99%

Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: A meta-analysis

Premraj

Kannapadi

Briggs

et al. 2022

Journal of the Neurological Sciences

539

326

View full text Add to dashboard Cite

Importance: Neurological and neuropsychiatric symptoms that persist or develop three months after the onset of COVID-19 pose a significant threat to the global healthcare system. These symptoms are yet to be synthesized and quantified via meta-analysis. Objective: To determine the prevalence of neurological and neuropsychiatric symptoms reported 12 weeks (3 months) or more after acute COVID-19 onset in adults. Data sources: A systematic search of PubMed, EMBASE, Web of Science, Google Scholar and Scopus was conducted for studies published between January 1st, 2020 and August 1st, 2021. The systematic review was guided by Preferred Reporting Items for Systematic Review and Meta-Analyses. Study selection: Studies were included if the length of follow-up satisfied the National Institute for Healthcare Excellence (NICE) definition of post-COVID-19 syndrome (symptoms that develop or persist ≥3 months after the onset of COVID-19). Additional criteria included the reporting of neurological or neuropsychiatric symptoms in individuals with COVID-19. Data extraction and synthesis: Two authors independently extracted data on patient characteristics, hospital and/ or ICU admission, acute-phase COVID-19 symptoms, length of follow-up, and neurological and neuropsychiatric symptoms. Main outcome(s) and measure(s):The primary outcome was the prevalence of neurological and neuropsychiatric symptoms reported ≥3 months post onset of COVID-19. We also compared post-COVID-19 syndrome in hospitalised vs. non-hospitalised patients, with vs. without ICU admission during the acute phase of infection, and with mid-term (3 to 6 months) and long-term (>6 months) follow-up. Results: Of 1458 articles, 19 studies, encompassing a total of 11,324 patients, were analysed. Overall prevalence for neurological post-COVID-19 symptoms were: fatigue (37%, 95% CI: 24%-50%), brain fog (32%, 9%-55%), memory issues (27%, 18%-36%), attention disorder (22%, 10%-34%), myalgia (18%, 4%-32%), anosmia (12%, 7%-17%), dysgeusia (11%, 4%-17%) and headache (10%, 1%-21%). Neuropsychiatric conditions included sleep disturbances (31%, 18%-43%), anxiety (23%, 13%-33%) and depression (12%, 7%-21%). Neuropsychiatric symptoms substantially increased in prevalence between mid-and long-term follow-up. Compared to nonhospitalised patients, patients hospitalised for acute COVID-19 had reduced frequency of anosmia, anxiety,

show abstract

Post-COVID symptoms reported at asynchronous virtual review and stratified follow-up after COVID-19 pneumonia

Cited by 33 publications

References 30 publications

Associations of Post-Acute COVID syndrome with physiological and clinical measures 10 months after hospitalization in patients of the first wave

Associations of Post-Acute COVID syndrome with physiological and clinical measures 10 months after hospitalization in patients of the first wave

Post-traumatic Stress Disorder Symptoms and Quality of Life of COVID-19 Survivors at 6-Month Follow-Up: A Cross-Sectional Observational Study

Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: A meta-analysis

Contact Info

Product

Resources

About